FDA Final OTC Hearing Aid Rules Move Forward from OMB

The FDA’s final regulations for over-the-counter (OTC) hearing aids are nearing publication, following completion of the Office of Information and Regulatory Affairs’ (OIRA) review on August 5. The rulemaking process began with the passage of the OTC Hearing Aid Act in March 2017 and the subsequent signing of the FDA Reauthorization Act of 2017 (FDARA), but has been delayed for five years, surpassing the original statutory deadline of August 18, 2020. The delay is attributed to the pandemic’s strain on FDA resources, a backlog of work, and complexities related to aligning federal regulations with state-level hearing aid dispensing laws. Congressional pressure, including a bill introduced by Senators Chuck Grassley and Elizabeth Warren in April 2023 demanding prompt finalization of the rules, has further highlighted the urgency for these regulations. The proposed rules, first published in October 2021, aim to establish a new class of self-fitting air-conduction devices for adults with m
Otc Hearing Aids 1200 X 675

The FDA’s final regulations for OTC hearing aids appear to be at or near the publication stage. According to an online post by the Office of Information and Regulatory Affairs (OIRA), the review of the US Food and Drug Administration’s (FDA) final proposed rules for over-the-counter (OTC) hearing aids was completed by the Office of Management and Budget (OMB) on August 5. Presumably, this would mean the document is back in the hands of FDA for final consideration and revision. 

Otc Hearing Aids 1200 X 675

The OIRA had up to 90 days to complete its review, but took less than 30 days after receiving the FDA guidance. Although it’s unknown how much further work and review is needed by the FDA for completion of the final regulations, the OIRA’s conclusion of the guidance review would suggest publication of the final rules is near.

The rulemaking technically started with the OTC Hearing Aid Act in March 2017 and the signing of the FDA Reauthorization Act of 2017 (FDARA) by President Trump in August 2017. Thus, they have been 5 years in the making—blowing through the original statutory deadline of August 18, 2020 set by Congress. Without a doubt, the pandemic’s demand on FDA resources, the Agency’s subsequent backlog of work, and the complexity surrounding OTC hearing aid rules—particularly regarding individual state regulations for hearing aid dispensing—has contributed to the delay.

Fda

In particular, the FDA has been under intense pressure by Senators Chuck Grassley (R-IA), Elizabeth Warren (D-MA), and other members of Congress, as well as the Biden Administration, to “finalize the rule without delay and in a manner that is consistent with congressional intent.” Senators Grassley and Warren introduced a bill on April 7 which would force the agency to “issue a final rule within 30 days following enactment.” The two senators also issued a strong follow-up letter, as well as a report on June 29 accusing the “Big 5” hearing aid manufacturers of an “astroturf” lobbying campaign to influence FDA and weaken the OTC rule. (For more information, see the HearingTracker article “Over the Counter Hearing Aids” which includes at the bottom a timeline of significant events in the genesis and evolution of the rules.)

The final FDA OTC hearing aid regulations will provide manufacturers and dispensing professionals with rules for a new class of self-fitting air-conduction devices intended for adults (ages 18+ years). Designed to make hearing aids more affordable and accessible for people with mild-to-moderate hearing loss, the proposed regulations published on October 20, 2021 were far more extensive than most people expected. It essentially called for a clean slate when it comes to the various state dispensing laws, although it appeared that licensure laws would remain intact unless they violated the original intent of the OTC regulations. Among the most consequential and controversial regulatory issues at stake are loudness limits, electroacoustic and 510(k) premarket notification requirements, returns-for-credit and consumer recourse, and a wide range of labeling issues.

This article is still being edited.

The above is the interpretation of FDA Final OTC Hearing Aid Rules Move Forward from OMB provided by Chinese hearing aid supplier Shenrui Medical. Link https://www.sengdong.com/Blog/FDA-Final-OTC-Hearing-Aid-Rules-Move-Forward-from-OMB.html of this article is welcome to share and forward. For more hearing aid related information, please visit Blog or take a look at our Hearing aids products

Hot Posts